Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.54 |
| ▸ | DRD3 | P35462 | 11/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.43 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.43 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125283 | 0.81 | DRD2 (0.47) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL28958186 | 0.81 | DRD2 (0.47) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL4875328 | 0.80 | DRD2 (0.67) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL31523251 | 0.77 | DRD2 (0.73) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL2227921 | 0.75 | DRD2 (0.71) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL14869628 | 0.75 | DRD2 (0.76) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL4071635 | 0.74 | DRD2 (0.59) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| Hydrochloric Acid SCHEMBL31210148 | 0.74 | DRD2 (0.73) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL31585242 | 0.74 | DRD3 (0.55) | DRD2DRD3CYP2D6TSHRNFKB1 | |
| SCHEMBL31083652 | 0.74 | DRD2 (0.47) | DRD2DRD3CYP2D6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4476230-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154291-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154291-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122218-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | DRD2 4638/4885DRD3 4651/4885CYP2D6 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.